Biotech News
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
investors.pulmonx.com2026-05-06 14:58 EST
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading